Ulcerative colitis - Treatment
Treatment in Ulcerative colitis aims at inducing remission, and maintaining obtained remission. Supplementation with nutritional elements is rarely needed.
- Steroids: Have shown to be effective in the short-term perspective in inducing remission. Steroids are not used in maintenance therapy due to lack of effect in combination with high risk of side effects.
- Aminosalycylates: Are considered safe, but with limited effect in severe Ulcerative colitis. Despite this profile, Aminosalycylates are considered to be a first-line drug, especially in mild forms of the disease.
- Immunosuppressant: Less documentation is available regarding immunosuppressant role in Ulcerative colitis compared to Crohn’s disease. Due to a more pronounced risk for severe side effects, immunomudulators are regarded as third-line drugs.
- Adacolumn® apheresis: Is a new and unique, non-pharmacological approach in Ulcerative colitis. Instead of administrating a drug, the Adacolumn® apheresis system reduces the ongoing inflammation by adsorbing over-activated white blood cells from the circulation, thereby reducing the inflammatory burden, without the risk of side effects attributed to drugs.
- Surgical treatment: In approximately 50% of Ulcerative colitis patients, surgical intervention will be needed at some time. It is believed that recent advances in the treatment of Ulcerative colitis will reduce the number of patients in need of surgery.